Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS: Trabectedin/PLD vs Standard Platinum Therapy in Recurrent Ovarian Cancer
NCT03164980Phase 4Terminated
- Sponsor
- NOGGO
- Start
- Feb 2018
- Primary completion
- Aug 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trabectedin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by NOGGO. Started Feb 2018; status: terminated.
02
Drugs
trabectedin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03164980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164980.